PublicWire | Emerging Market Stock News
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
No Result
View All Result
PublicWire
No Result
View All Result

Home » Cannabis » Operational Update: Aurora Cannabis Surpasses 12,000 Registered Patients in First 12 Months of Product Sales

Operational Update: Aurora Cannabis Surpasses 12,000 Registered Patients in First 12 Months of Product Sales

by Randy Whitney
April 27, 2019
in Cannabis
Reading Time: 3 mins read
0

Canada NewsWire, ACBFF

VANCOUVER, Jan. 16, 2017

TSXV: ACB

VANCOUVER, Jan. 16, 2017 /CNW/ – Aurora Cannabis Inc. (“Aurora” or the “Company”) (TSXV: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) is pleased to provide the following operational update.

Patient Registration Continues Rapid Pace

On December 21, 2016, Aurora surpassed 12,000 active registered patients, less than 12 months after the Company’s first product sale in January, 2016, which is believed to be the fastest rate of patient registration after commencement of commercial operations achieved by any Licensed Producer.

Recall of Product Purchased Wholesale

On January 13, 2017, Aurora initiated a voluntary recall of product purchased from another licensed producer and resold to clients. The other licensed producer had previously initiated a precautionary voluntary product recall, which affected a relatively small quantity of product resold by Aurora. The recall is not anticipated to have material financial or operational consequences for Aurora.

Aurora Sky Construction Update

Construction of the Company’s new Aurora Sky production facility at Edmonton International Airport (“EIA”) is progressing smoothly and on schedule, with grade and fill work essentially complete. More than 400 screw piles are now installed for the grade beam, and office trailers and other infrastructure have been completed at the site. The General Contractor award is will be announced shortly, with Subtrade awards following thereafter. Construction of the facility is expected to be completed on schedule as planned for the second half of 2017.

Radient Technologies Joint Venture Research Agreement

On January 4, 2017, Aurora signed a Joint Venture Research Agreement with Radient Technologies Inc. (“RTI”). The first phase of this venture will include screening experiments of extraction conditions, while phase two includes larger scale experiments related to extraction throughput and optimal extraction conditions. Aurora’s scientists and the RTI team will commence tests January 16, 2017, and the first phase is expected to be completed within approximately six weeks.

Legal Update

Further to the Company’s news release dated March 4, 2016, Aurora has now settled both outstanding legal proceedings and as such, is no longer involved in any further litigation.

About Aurora

Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) and operates a 55,200 square foot, expandable, state-of-the-art production facility in Mountain View County, Alberta, Canada. Aurora trades on the TSX Venture Exchange under the symbol “ACB”.

On behalf of the Board of Directors,
AURORA CANNABIS INC.

Terry Booth
CEO

This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Aurora Cannabis Inc.

Copyright © 2017 PR Newswire. All Rights Reserved

Tags: ACBACBFFAurora Cannabis Inc.Aurora Skymedical cannabis
Previous Post

Lifestyle Delivery Systems Inc. Announces Its Intention to Conduct Clinical Trails of CannaStrips in Canada

Next Post

ProtoKinetix, Incorporated Announces Investigator Sponsored Clinical Trial Submitted to Health Canada for the use of AAGP™ in the Treatment of Type 1 Diabetes

Randy Whitney

Randy is a marketing specialist with experience creating content for sports and real estate in New York City. He has written for Major League Baseball and Cut4 as well as contributed creatively to the growth and development of startups around the country.

Related Posts

Photo by GRAS GRÜN on Unsplash
Cannabis

Zenabis returned $1.9 million worth of pot to Sundial over bad quality and visible molds

August 22, 2019
0
Photo by Rick Proctor on Unsplash
Cannabis

Tilray to start exporting medicinal pot to Germany

August 21, 2019
0
Photo by Esteban Lopez on Unsplash
Cannabis

CannTrust stocks fell another 5% after weed distributor returned millions worth of pot

August 20, 2019
0
Photo by Roberto Valdivia on Unsplash
Cannabis

Cannabis stocks fell as possible recession brews

August 14, 2019
0
Cannabis

Aurora Cannabis hovers trade flat amid strong market

August 13, 2019
0
Photo by Get Budding on Unsplash
Cannabis

Health inspectors flagged CannTrust’s non-compliance again, sending stocks down by 26%

August 12, 2019
0
Next Post

ProtoKinetix, Incorporated Announces Investigator Sponsored Clinical Trial Submitted to Health Canada for the use of AAGP™ in the Treatment of Type 1 Diabetes

Please login to join discussion

Subscribe To Our Newsletter

Loading
Ad
PublicWire | Emerging Market Stock News 24/7 | Investor Relations US Stock Market

© Copyright 2022 publicwire.com

Navigate Site

  • About
  • Contact Us
  • Disclaimer
  • Watch LIVE
  • Privacy Policy
  • Terms and Services
  • Contributors

Follow Us

No Result
View All Result
  • LIVE Investor News Channel
  • Cannabis
  • Energy
  • Finance
  • General
  • Medical
  • Podcasts
  • Retail
  • Technology
  • Videos

© Copyright 2022 publicwire.com

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.